Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | NNMT | P40261 | 2/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27038213 | 1.00 | EGFR (0.37) | EGFRNNMTMAP4K1MAPK1HSD11B1 | |
| SCHEMBL27037721 | 0.84 | NNMT (0.32) | NNMT | |
| SCHEMBL30698968 | 0.84 | NNMT (0.32) | NNMT | |
| SCHEMBL27038227 | 0.83 | NNMT (0.35) | NNMT | |
| SCHEMBL31473805 | 0.83 | NNMT (0.35) | NNMT | |
| SCHEMBL31473839 | 0.83 | NNMT (0.31) | NNMT | |
| SCHEMBL31473654 | 0.82 | NNMT (0.31) | NNMT | |
| SCHEMBL31473665 | 0.82 | DPP4 (0.34) | NNMT | |
| SCHEMBL31473753 | 0.81 | NNMT (0.30) | NNMT | |
| SCHEMBL31473861 | 0.81 | KDM4E (0.34) | EGFRNNMTMAP4K1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | EGFR 495/4885NNMT 1091/4885MAP4K1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.